Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John D Hainsworth, M.D.
SCRI Development Innovations, LLC
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Florida Hospital Cancer Insitute
Orlando, Florida, United States
- Norton Cancer Institute
Louisville, Kentucky, United States
- Nebraska Methodist Cancer Center
Omaha, Nebraska, United States
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
- Ut Cancer Insititute Memphis
Memphis, Tennessee, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
- Peninsula Cancer Institute
Newport News, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2010
- Primary completion
- 31 Jul 2014
- Completion
- 31 Jul 2014
- Last update posted
- 10 Nov 2021
- Registered enrollment
- 18
- Registry id
- NCT00972335
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.